Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Associated Therapies: -

Clinical Trials

Collaborative Urological Prosthetics Investigation Directive Research Group

Early Phase 1

Active, not recruiting

Conditions: Erectile Dysfunction
Penile Prosthesis Infection

Interventions: Drug: Doxycycline
Drug: Ciprofloxacin
Drug: Augmentin
Drug: Bactrim

First Posted Date: 2021-10-29

Last Posted Date: 2024-02-07

Lead Sponsor: University of Chicago

Target Recruit Count: 800

Registration Number: NCT05100654

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

Phase 4

Recruiting

Conditions: Febrile Neutropenia

Interventions: Drug: Piperacillin and Tazobactam for Injection
Drug: Cefepime Injection
Drug: Ceftazidime Injection
Drug: Vancomycin Injection
Drug: Amikacin Injection
Drug: Ciprofloxacin

First Posted Date: 2021-07-02

Last Posted Date: 2024-03-15

Lead Sponsor: Murdoch Childrens Research Institute

Target Recruit Count: 312

Registration Number: NCT04948463

Locations: 🇦🇺
Royal Children's Hospital, Melbourne, Victoria, Australia

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

Phase 1

Completed

Conditions: Gonococcal Infection

Interventions: Drug: Azithromycin
Drug: Ceftriaxone
Drug: Ciprofloxacin
Biological: Neisseria gonorrhoeae strain FA1090 A26
Biological: Neisseria gonorrhoeae strain FA7527

First Posted Date: 2021-05-03

Last Posted Date: 2021-12-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT04870138

Locations: 🇺🇸
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States

Antibiotic Prophylaxis for Neurogenic Bladder Botox

Phase 2

Not yet recruiting

Conditions: Neurogenic Bladder
Post-operative Urinary Tract Infections

Interventions: Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2021-03-10

Last Posted Date: 2024-12-17

Lead Sponsor: University of Alberta

Target Recruit Count: 160

Registration Number: NCT04791579

Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.

Phase 3

Withdrawn

Conditions: Febrile Neutropenia

Interventions: Drug: Amoxicillin Clavulanate
Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2021-01-06

Last Posted Date: 2022-03-31

Lead Sponsor: Poitiers University Hospital

Registration Number: NCT04698057

CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)

Not Applicable

Recruiting

Conditions: Acute Lymphoblastic Leukaemia - Category

Interventions: Drug: Ciprofloxacin
Drug: Antibiotic

First Posted Date: 2020-12-22

Last Posted Date: 2024-03-08

Lead Sponsor: University College, London

Target Recruit Count: 1052

Registration Number: NCT04678869

Locations: 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
🇬🇧
Nottingham Children's Hospital, Nottingham, United Kingdom
🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom

and more 11 locations